Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BOS complex subunit NOMO2 (NODAL modulator 2, NOMO2) is a membrane-associated protein involved as a component of the multi-pass translocon (MPT) complex, which mediates the insertion of multi-pass membrane proteins into the lipid bilayer of cellular membranes, particularly in the endoplasmic reticulum[1][10][2][3]. This protein is not a canonical therapeutic target such as a receptor or enzyme; instead, it plays a role as part of the cellular machinery responsible for membrane protein biogenesis. NOMO2 is also implicated in the Nodal signaling pathway during vertebrate development[1][6]. While it has been annotated in the proximity of disease loci, there is no strong evidence implicating it directly as a disease-driving protein or druggable target. **Note on context:** NOMO2 is not generally considered a therapeutic target (such as a druggable receptor or enzyme) in current biomedical practice or research[1][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BOS complex subunit NOMO2 (NOMO2).